Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good day, and thank you for standing by. Welcome to the Myriad ...

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the ...

A new approach reveals genetic interactions that contribute to heart defects. Scientists at the Icahn School of Medicine at ...

In response to a recent reader inquiry regarding the degree of heterosis he could expect in his breeding program, we thought ...

Testing is recommended for those with personal and family histories of several types of cancer — including pancreatic and ...

周二，Jefferies分析师将Myriad Genetics的目标股价从此前的$13.00下调至$11.00，同时维持对该公司股票的低配评级。目前该股交易价格为$13.78，根据InvestingPro数据显示，过去六个月股价大幅下跌51%。此次目标价调整是在该公司1月份发布预告以及2025年展望后作出的，其中包括了首席执行官变更的消息。

这项研究为髓母细胞瘤在小脑发育过程中如何发生提供了新的见解。研究人员发现，同一基因ZIC1可以通过不同的、特定环境相关的机制驱动高度相似的癌症。研究人员分析了G4和SHH两种类型的髓母细胞瘤，这两种类型被认为起源于小脑发育过程中的同一细胞。通过基因组 ...

周二，摩根大通分析师Rachel Vatnsdal将Myriad Genetics（NASDAQ:MYGN）的目标股价从此前的15.00美元下调至12.00美元，同时维持对该股票的减持评级。此次调整是在Myriad Genetics周一收市后发布第四季度财报之后做出的。

To do that, they focused especially closely on a subset of 45,000 people whose blood samples had been subjected to what is ...

Ancient DNA traces the Huns' journey from Mongolia to Europe. But this wasn't straightforward.

The new project will utilize AI to determine how methods used to analyze animal and plant genetic databases could benefit the ...